A Global Health Problem.
Despite advances in care, the hepatitis C virus (HCV) remains a global health problem, requiring continued collaborative action to elevate awareness, increase diagnosis and improve linkage to care for all people living with the disease.
Read About Our Latest Efforts in HCV
AbbVie Announces Approval of MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in Japan
European Commission Grants AbbVie’s MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
AbbVie Receives CHMP Positive Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
About Hepatitis C
Hepatitis C is an infectious liver disease resulting from infection with HCV.1
It typically spreads when blood from an infected person enters the body of someone who is not infected.1
71 million people are infected with HCV worldwide.2 The reported incidence of new infections is estimated at nearly 24 cases per 100,000 people annually. Since the disease often has no symptoms, the actual incidence may be much higher.2
The millions of people living with HCV have varied needs, depending on their specific genotype, fibrosis stage and other characteristics.
Hepatitis C often shows no symptoms. 80% of the people living with HCV are unaware of their infection status.3,4 Of the 71 million people living with HCV infection globally, only 20% or 14 million are diagnosed.2
Many people live in countries where hepatitis C testing is largely inaccessible.5 This lack of access to testing and the asymptomatic nature of the disease contributes to a low diagnosis rate.
The Burden of HCV
Hepatitis C leads to serious health consequences, which can ultimately result in death. The human, social and economic costs of HCV are high and increase as the disease progresses.
Over time, HCV can cause liver cirrhosis and liver cancer.1,3,6 Approximately 399,000 people die each year from hepatitis C-related liver disease.2
HCV carries significant stigma, which can impact a person’s quality of life including self-esteem, relationships, productivity and mental health.7
HCV places an enormous economic toll on society due to lower quality of life in patients and increasing healthcare costs in later stages of the disease.8,9,10
1. Hepatitis C: General Information. Centers for Disease Control and Prevention Web site. https://www.cdc.gov/hepatitis/hcv/pdfs/hepcgeneralfactsheet.pdf.
2. World Health Organization. Global hepatitis report 2017. http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1.
3. Hepatitis C. World Health Organization. World Health Organization, July 2016. Web. http://www.who.int/mediacentre/factsheets/fs164/en/.
4. Negro, Francesco. "Epidemiology of Hepatitis C in Europe." Digestive and Liver Disease 46 (2014): S158-164.
5. Viral Hepatitis: Global Policy. World Hepatitis Alliance. http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&gid=18148&Itemid=270.
6. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol (2016), http://dx.doi.org/10.1016/j.jhep.2016.09.001.
7. Miller ER, McNally S Wallace J Schlichthorst M. The ongoing impacts of hepatitis c - a systematic narrative review of the literature. BMC Public Health. 2012; 12:672.
8. Su J et al. The Impact of Hepatitis C Virus Infection on Work Absence, Productivity, and Healthcare Benefit Costs. Hepatology 2010;52(2):436–442.
9. El Khoury AC, Vietri J, Prajapati G. The burden of untreated hepatitis C virus infection: a US patients' perspective. Dig Dis Sci. 2012; 57(11):2995-3003.
10. McAdam-Marx C et al. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm. 2011;17:531-46.